These results confirmed that the HF2S significantly inhibited CML cell proliferation by down-regulation of the kinase activities of MAPK-Akt and STAT5 pathways. The gene discussed is AKT1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.